AU Patent

AU2020322881B2 — Pyrimidine compound acting on EGFR and ERBB2

Assigned to China Resources Pharmaceutical Holdings Co Ltd · Expires 2023-08-10 · 3y expired

What this patent protects

Disclosed is a pyrimidine compound acting on an EGFR exon 20 insertion mutation and an ERBB2 exon 20 insertion mutation or a pharmaceutically acceptable salt thereof.

USPTO Abstract

Disclosed is a pyrimidine compound acting on an EGFR exon 20 insertion mutation and an ERBB2 exon 20 insertion mutation or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020322881B2
Jurisdiction
AU
Classification
—
Expires
2023-08-10
Drug substance claim
No
Drug product claim
No
Assignee
China Resources Pharmaceutical Holdings Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.